Innovation in Targeted Intra-articular Therapies for Osteoarthritis

[1]  Y. Yazici,et al.  A Phase 2, 104-Week Study Of Repeat Lorecivivint Injections Evaluating Safety, Efficacy, And Bone Health Utlizing Quantitative Computed Tomography In Knee Osteoarthritis (Oa-06) , 2023, Osteoarthritis and Cartilage.

[2]  J. Goldhahn,et al.  Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial , 2022, Nature Medicine.

[3]  A. Agarwal,et al.  Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis , 2022 .

[4]  Vandana Sood,et al.  Prevalence of rapidly progressive osteoarthritis of the hip following intra‐articular steroid injections , 2022, PM & R : the journal of injury, function, and rehabilitation.

[5]  M. Schieker,et al.  CARTILAGE REGENERATION AFTER TREATMENT WITH LNA043, A NOVEL DISEASE-MODIFYING OSTEOARTHRITIS DRUG CANDIDATE: RESULTS FROM AN IMAGING-BASED PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH FOCAL ARTICULAR CARTILAGE LESIONS IN THE KNEE , 2022, Osteoarthritis and Cartilage.

[6]  A. Guermazi,et al.  SEMI-QUANTITATIVE AND QUANTITATIVE CARTILAGE IMPROVEMENT AFTER INTRA-ARTICULAR INJECTION OF ICM-203 IN CANINE OA MODEL , 2022, Osteoarthritis and Cartilage.

[7]  F. Guillemin,et al.  Do Glucocorticoid Injections Increase the Risk of Knee Osteoarthritis Progression Over 5 Years? , 2022, Arthritis & rheumatology.

[8]  D. Hunter,et al.  TLC599 in patients with osteoarthritis of the knee: a phase IIa, randomized, placebo-controlled, dose-finding study , 2022, Arthritis Research & Therapy.

[9]  N. Lane,et al.  Synovial inflammation in osteoarthritis progression , 2022, Nature Reviews Rheumatology.

[10]  P. M. van der Kraan.  Inhibition of transforming growth factor-β in osteoarthritis. Discrepancy with reduced TGFβ signaling in normal joints , 2022, Osteoarthritis and cartilage open.

[11]  F. Berenbaum,et al.  Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis , 2022, Scientific Reports.

[12]  M. Reijnierse,et al.  Administration of an adeno-associated viral vector expressing interferon-β in patients with inflammatory hand arthritis, results of a phase I/II study. , 2021, Osteoarthritis and cartilage.

[13]  N. Segal,et al.  Study TPX-100-5: intra-articular TPX-100 significantly delays pathological bone shape change and stabilizes cartilage in moderate to severe bilateral knee OA , 2021, Arthritis Research & Therapy.

[14]  A. Malone,et al.  Safety and pharmacokinetics of EP-104IAR (sustained-release fluticasone propionate) in knee osteoarthritis: A randomized, double-blind, placebo-controlled phase 1 trial , 2021, Osteoarthritis and cartilage open.

[15]  M. Schieker,et al.  POS0277 ANABOLIC EFFECT OF LNA043, A NOVEL DISEASE-MODIFYING OSTEOARTHRITIS DRUG CANDIDATE: RESULTS FROM AN IMAGING-BASED PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH FOCAL ARTICULAR CARTILAGE LESIONS , 2021 .

[16]  L. Yao,et al.  Rapidly progressive idiopathic arthritis of the hip: incidence and risk factors in a controlled cohort study of 1471 patients after intra-articular corticosteroid injection , 2021, Skeletal Radiology.

[17]  F. Eckstein,et al.  Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study , 2021, Annals of the Rheumatic Diseases.

[18]  N. Segal,et al.  Interim results: the effect of intra-articular extended-release triamcinolone acetonide on OARSI-recommended physical performance measures in adults with bilateral symptomatic knee OA , 2021 .

[19]  Y. Nishida,et al.  Efficacy and Safety of Diclofenac–Hyaluronate Conjugate (Diclofenac Etalhyaluronate) for Knee Osteoarthritis: A Randomized Phase III Trial in Japan , 2021, Arthritis & rheumatology.

[20]  F. Eckstein,et al.  The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial. , 2021, Seminars in arthritis and rheumatism.

[21]  M. Hochberg,et al.  A Phase 2b Randomized Trial of Lorecivivint, a Novel Intra-articular CLK2/DYRK1A Inhibitor and Wnt Pathway Modulator for Knee Osteoarthritis. , 2021, Osteoarthritis and cartilage.

[22]  J. Katz,et al.  Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. , 2021, JAMA.

[23]  B. Dube,et al.  Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative , 2020, Annals of the Rheumatic Diseases.

[24]  C. Altier,et al.  TRPV1-Targeted Drugs in Development for Human Pain Conditions , 2020, Drugs.

[25]  M. Blankstein,et al.  Common Practices in Intra-Articular Corticosteroid Injection for the Treatment of Knee Osteoarthritis: A Survey of the American Association of Hip and Knee Surgeons Membership. , 2020, The Journal of arthroplasty.

[26]  S. L. Yadav,et al.  Assessment of pain and structure after an intra-articular injection of adalimumab in osteoarthritis of the knee , 2020, Medicine.

[27]  M. Hochberg,et al.  Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial , 2020, Arthritis & rheumatology.

[28]  Lingyun Sun,et al.  Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017 , 2020, Annals of the Rheumatic Diseases.

[29]  R. Lories,et al.  Review Article: Is Wnt Signaling an Attractive Target for the Treatment of Osteoarthritis? , 2020, Rheumatology and Therapy.

[30]  Matthew S. Tremblay,et al.  Development of KA34 as a cartilage regenerative therapy for Osteoarthritis , 2020 .

[31]  N. Lane,et al.  Safety, tolerability, pharmacokinetics, and clinical outcomes following treatment of painful knee osteoarthritis with senolytic molecule UBX0101 , 2020, Osteoarthritis and Cartilage.

[32]  G. Guyatt,et al.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee , 2020, Arthritis care & research.

[33]  Felix Eckstein,et al.  Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial. , 2019, JAMA.

[34]  B. Melchior,et al.  Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. , 2019, Osteoarthritis and cartilage.

[35]  G. Hawker.  Osteoarthritis is a serious disease. , 2019, Clinical and experimental rheumatology.

[36]  G-L Jiang,et al.  Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study. , 2019, Osteoarthritis and cartilage.

[37]  R. Burges,et al.  Randomized, Double‐Blind, Placebo‐Controlled Trial of Intraarticular Trans‐Capsaicin for Pain Associated With Osteoarthritis of the Knee , 2019, Arthritis & rheumatology.

[38]  J H Abbott,et al.  OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. , 2019, Osteoarthritis and cartilage.

[39]  Hui Li,et al.  Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative. , 2019, Osteoarthritis and cartilage.

[40]  Myoung-Mook Lee,et al.  Long-term follow-up assessment of the safety and efficacy of INVOSSA-K INJ., a novel cell mediated gene therapy for treatment of osteoarthritis , 2019, Osteoarthritis and Cartilage.

[41]  C. Peterfy,et al.  Safety and Efficacy of Repeat Administration of Triamcinolone Acetonide Extended-release in Osteoarthritis of the Knee: A Phase 3b, Open-label Study , 2019, Rheumatology and Therapy.

[42]  Shawn W. Polson,et al.  Identification of Chondrocyte Genes and Signaling Pathways in Response to Acute Joint Inflammation , 2019, Scientific Reports.

[43]  G. Herrero-Beaumont,et al.  2018 update of the EULAR recommendations for the management of hand osteoarthritis , 2018, Annals of the rheumatic diseases.

[44]  G. R. Dodge,et al.  Sprifermin treatment enhances cartilage integration in an in vitro repair model , 2018, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[45]  Z. McCormick,et al.  Efficacy of Injected Corticosteroid Type, Dose, and Volume for Pain in Large Joints: A Narrative Review , 2018, PM & R : the journal of injury, function, and rehabilitation.

[46]  B. Cole,et al.  Intra-articular injection of the anti-inflammatory compound LMWF-5A in adults with severe osteoarthritis: a double-blind prospective randomized controlled multi-center safety and efficacy trial , 2018, Patient Safety in Surgery.

[47]  D. Jevsevar,et al.  Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain , 2018, The Journal of bone and joint surgery. American volume.

[48]  N. Lane,et al.  TPX-100 leads to marked, sustained improvements in subjects with knee osteoarthritis: pre-clinical rationale and results of a controlled clinical trial , 2018 .

[49]  T. O’Neill,et al.  Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. , 2018, Best practice & research. Clinical rheumatology.

[50]  B. Lee.  INVOSSA, a first-in-class of cell and gene therapy for osteoarthritis treatment: the phase III trial , 2018 .

[51]  Ju-Hong Lee,et al.  A Multicenter, Double-Blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of a Cell and Gene Therapy in Knee Osteoarthritis Patients. , 2018, Human gene therapy. Clinical development.

[52]  M. Karsdal,et al.  Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo , 2017, Journal of Translational Medicine.

[53]  B. Cole,et al.  LMWF-5A for the Treatment of Severe Osteoarthritis of the Knee: Integrated Analysis of Safety and Efficacy. , 2017, Orthopedics.

[54]  A. Guermazi,et al.  Structural effects of intra-articular TGF-β1 in moderate to advanced knee osteoarthritis: MRI-based assessment in a randomized controlled trial , 2017, BMC Musculoskeletal Disorders.

[55]  M. Karsdal,et al.  Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. , 2017, Osteoarthritis and cartilage.

[56]  S. Çamur,et al.  COMPARED EFFICACY OF INTRA-ARTICULAR INJECTION OF METHYLPREDNISOLONE AND TRIAMCINOLONE , 2017, Acta ortopedica brasileira.

[57]  Jianping Wang.  Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial , 2017, The Journal of international medical research.

[58]  G. Vásárhelyi,et al.  Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial , 2017, Cartilage.

[59]  Jeffrey B. Driban,et al.  Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial , 2017, JAMA.

[60]  J. Elisseeff,et al.  Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment , 2017, Nature Medicine.

[61]  A. Bihlet,et al.  Trial design of SB-061 in osteoarthritis of the knee. The modify-OA trial , 2017 .

[62]  Philip G Conaghan,et al.  Synovitis in osteoarthritis: current understanding with therapeutic implications , 2017, Arthritis Research & Therapy.

[63]  K. Uchida,et al.  Nerve Growth Factor Regulation by TNF-α and IL-1β in Synovial Macrophages and Fibroblasts in Osteoarthritic Mice , 2016, Journal of immunology research.

[64]  Seung-Baik Kang,et al.  Invossa™(Tissuegene-C) in patients with osteoarthritis: A phase III trial , 2016 .

[65]  E. Vignon,et al.  When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program , 2016, Arthritis & rheumatology.

[66]  J. Grieger,et al.  Safety and biodistribution assessment of sc-rAAV2.5IL-1Ra administered via intra-articular injection in a mono-iodoacetate-induced osteoarthritis rat model , 2016, Molecular therapy. Methods & clinical development.

[67]  J. Parvizi,et al.  Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee. , 2015, Osteoarthritis and cartilage.

[68]  F. Cicuttini,et al.  Editorial: Pain Relief in Osteoarthritis: The Potential for a Perfect Storm , 2015, Arthritis & rheumatology.

[69]  S. Kishida,et al.  Efficacy of Direct Injection of Etanercept into Knee Joints for Pain in Moderate and Severe Knee Osteoarthritis , 2015, Yonsei medical journal.

[70]  A. Lomonte,et al.  Efficacy of Triamcinolone Hexacetonide versus Methylprednisolone Acetate Intraarticular Injections in Knee Osteoarthritis: A Randomized, Double-blinded, 24-week Study , 2015, The Journal of Rheumatology.

[71]  A. Fioravanti,et al.  Possible chondroprotective effect of canakinumab: an in vitro study on human osteoarthritic chondrocytes. , 2015, Cytokine.

[72]  J. Moloo.  Comparative Effectiveness of Pharmacologic Interventions for Knee Osteoarthritis , 2015 .

[73]  F. Eckstein,et al.  Intraarticular Sprifermin (Recombinant Human Fibroblast Growth Factor 18) in Knee Osteoarthritis: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2014, Arthritis & rheumatology.

[74]  K. Salottolo,et al.  A Randomized Clinical Trial to Evaluate Two Doses of an Intra-Articular Injection of LMWF-5A in Adults with Pain Due to Osteoarthritis of the Knee , 2014, PloS one.

[75]  M. Gotoh,et al.  Cyclic phosphatidic acid relieves osteoarthritis symptoms , 2014, Molecular pain.

[76]  R. Bolce,et al.  FRI0304 Treatment of knee osteoarthritis with intra-articular infliximab improves total womac score. High baseline levels of synovial cellularity predict improvement , 2013 .

[77]  A. Albayrak,et al.  Efficacy comparisons of the intraarticular steroidal agents in the patients with knee osteoarthritis , 2012, Rheumatology International.

[78]  W. Hauswirth,et al.  scAAV-Mediated Gene Transfer of Interleukin 1-Receptor Antagonist to Synovium and Articular Cartilage in Large Mammalian Joints , 2012, Gene Therapy.

[79]  Peter G. Schultz,et al.  A Stem Cell–Based Approach to Cartilage Repair , 2012, Science.

[80]  D. Nickerson,et al.  Intra‐articular gene delivery and expression of interleukin‐1Ra mediated by self‐complementary adeno‐associated virus , 2009, The journal of gene medicine.

[81]  D. Loeuille,et al.  Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. , 2009, Arthritis and rheumatism.

[82]  A. Fioravanti,et al.  Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study , 2009, Rheumatology International.

[83]  C. Maggi,et al.  Knee osteoarthritis: a role for bradykinin? , 2008, Inflammation Research.

[84]  G. Burmester,et al.  Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI , 2008, Annals of the rheumatic diseases.

[85]  D. Thompson,et al.  Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. , 2005, Osteoarthritis and cartilage.

[86]  B. Giraudeau,et al.  Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. , 2005, The Journal of rheumatology.

[87]  G. Martin,et al.  Albumin: Biochemical properties and therapeutic potential , 2005, Hepatology.

[88]  M. Buschmann,et al.  Fibroblast Growth Factor (FGF) 18 Signals through FGF Receptor 3 to Promote Chondrogenesis* , 2005, Journal of Biological Chemistry.

[89]  D. Pyne,et al.  Intra-articular steroids in knee osteoarthritis: a comparative study of triamcinolone hexacetonide and methylprednisolone acetate , 2004, Clinical Rheumatology.

[90]  Arden,et al.  EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) , 2003, Annals of the rheumatic diseases.

[91]  D. Thompson,et al.  Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. , 2002, Osteoarthritis and cartilage.

[92]  J. Hood,et al.  A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. , 2018, Osteoarthritis and cartilage.

[93]  P. Robbins,et al.  Gene Delivery to Joints by Intra-Articular Injection. , 2018, Human gene therapy.

[94]  M. Herrmann,et al.  IκB kinase inhibition as a potential treatment of osteoarthritis - results of a clinical proof-of-concept study. , 2017, Osteoarthritis and cartilage.

[95]  B. Cole,et al.  LMWF-5 A for the Treatment of Severe Osteoarthritis of the Knee : Integrated Analysis of Safety and Efficacy , 2017 .

[96]  F. Berenbaum,et al.  Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). , 2013, Osteoarthritis and cartilage.

[97]  Johanne Martel-Pelletier,et al.  Role of proinflammatory cytokines in the pathophysiology of osteoarthritis , 2011, Nature Reviews Rheumatology.

[98]  G. Thomas,et al.  A diketopiperazine fragment of human serum albumin modulates T-lymphocyte cytokine production through rap1. , 2008, The Journal of trauma.